Short answer
ResMed (RMD) filed its Q3 2026 10-Q quarterly report on Oct 30, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $1.4B (up 5.9% year over year) with net income of $418M.
Q3 2026 key financials · XBRL
- Revenue
- $1.4B
- +5.9% YoY
- Net income
- $418M
- +20.0% YoY
- Operating margin
- 32.0%
- Gross margin
- 61.5%
- EPS (diluted)
- $2.92
- +23.2% YoY
Source: XBRL data from the ResMed (RMD) Q3 2026 10-Q on SEC EDGAR. USD.
ResMed Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $1,415M, up $79M or 6% YoY
- Gross margin 61.5% vs 61.2% YoY; net income $418M vs $349M
- Best segment: Sleep and Breathing Health $1,260M, up 8%; worst: Residential Care Software $155M, down 7%
- Cash $1.0B vs $1.5B at June 30; operating cash flow $422M vs $457M
- $936M share repurchases and $250M debt repayment; inflationary component costs expected through fiscal 2027
Risk Factors
- No material changes to the fiscal 2026 Form 10-K risk factors as of September 30, 2026
- Carried-forward risks include regulatory compliance, product quality, cybersecurity, competition, and market demand
- Financial exposures remain those identified in the fiscal 2026 Form 10-K, including liquidity, debt, currency, and customer concentration risks
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other ResMed quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.